SynthesisBMC cancer2025
Efficacy of vaccination therapy in newly diagnosed and recurrent glioblastoma patients: a meta-analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vaccine-based cancer immunotherapy in newly diagnosed glioblastoma: a time-to-event meta-analysis of phase II and III randomized controlled trials.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics.Cancer innovation · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma (GB) is the most common and fatal primary central nervous system malignancy in adults. Various immunotherapies, including vaccination, are under investigation for their potential to extend survival in GB patients. Vaccination therapy has shown variable but promising outcomes across studies. This meta-analysis aims to evaluate the efficacy of available vaccines for newly diagnosed and recurrent GB.
methodsWe conducted a systematic search in PubMed, Scopus, and Web of Science to identify randomized or non-randomized double-arm studies involving adult GB patients treated with vaccines. Overall survival (OS) and progression-free survival (PFS) were the primary outcomes, with effect sizes represented as hazard ratios (HR) and calculated using a random-effects model. Funnel plots, Egger's and Begg-Mazumdar tests assessed publication bias, and the chi-square (Q) statistic, I
resultsA total of 2,792 patients from 23 clinical studies were included. Our findings showed significant improvements in PFS (HR, 0.64; p < 0.001) and OS (HR, 1.09; p < 0.00001) with minimal publication bias but notable heterogeneity. Meta-regression identified vaccine type and publication year as influential factors. Subgroup analysis demonstrated survival benefits with dendritic cell and viral vector vaccines, with a trend towards lower 6-methylguanine-DNA methyltransferase (MGMT) methylation rates. Sensitivity analysis confirmed the robustness of our results.
conclusionsVaccination therapy showed potential survival benefits for GB patients; however, further phase III studies are needed to validate these results, elucidate biological mechanisms, and strive for improved trial designs and patient stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.